Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas

Clinical Cancer Research

Volumn 11, Issue 5, 2005, Pages 1776-1785

  Fukumoto, Shin Ichi ^a,f   Yamauchi, Naoko ^b   Moriguchi, Hisashi ^a   Hippo, Yoshitaka ^a   Watanabe, Akira ^a   Shibahara, Junji ^b   Taniguchi, Hirokazu ^b   Ishikawa, Shumpei ^a   Ito, Hirotaka ^a   Yamamoto, Shogo ^a   Iwanari, Hiroko ^d   Hironaka, Mitsugu ^e   Ishikawa, Yuichi ^c   Niki, Toshiro ^b   Sohara, Yasunori ^e   Kodama, Tatsuhiko ^a   Nishimura, Masaharu ^f   Fukayama, Masashi ^b   Dosaka Akita, Hirotoshi ^f   Aburatani, Hiroyuki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c CANCER INSTITUTE   (Japan)

^d Perseus Proteomics   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

OXIDOREDUCTASE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REGRESSION ANALYSIS; SMOKING; STAINING; UPREGULATION;

ALDEHYDE REDUCTASE; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SMOKING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 20144387888     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1238     Document Type: Article

References (51)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 Suppl 8:S4-66.
2. American Cancer Society. Cancer facts and figures 2001. Atlanta: American Cancer Society; 2001.
3. Ries LAG, Hankey BF, Kosary CL, et al. SEER cancer statistics review, 1973-1991: tables and graphs. Vol. Pub. No. 94-2789. Bethesda (MD): NIH; 1994.
4. Carney DN. Lung cancer - time to move on from chemotherapy. N Engl J Med 2002;346:126-8.
5. Kinoshita I, Dosaka-Akita H, Mishina T, et al. Altered p16INK4A and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res 1996;56:5557-62.
6. Dosaka-Akita H, Fujino M, Harada M, et al. Altered retinoblastoma protein expression in non-small cell lung cancer: its synergistic effects with altered ras and p53 protein status on prognosis. Cancer (Phila) 1997;79:1329-37.
7. Hommura F, Dosaka-Akita H, Kinoshita I, et al. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers. Br J Cancer 1999;81:696-701.
8. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27KIP1 protein and Ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000;6:4073-81.
9. Mishina T, Dosaka-Akita H, Hommura F, et al. Cyclin E expression, a potential prognostic marker for non-small cell lung cancers. Clin Cancer Res 2000;6:11-6.
10. Dosaka-Akita H, Hommura F, Mishina T, et al. A risk-stratification model of non-small cell lung cancers using cyclin E, Ki-67, and ras p21: different roles of G1 cyclins in cell proliferation and prognosis. Cancer Res 2001;61:2500-4.
11. Dosaka-Akita H, Kinoshita I, Yamazaki K, et al. N-acetylgalactosaminyl transferase-3 is a potential new marker for non-small cell lung cancers. Br J Cancer 2002;87:751-5.
12. Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katoh H, Taniguchi N. Expression of N-acetylglucosaminyltransferase V is associated with prognosis and histology in non-small cell lung cancers. Clin Cancer Res 2004;10:1773-9.
13. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993;9:138-41.
14. Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene 2002;21:7307-25.
15. Pastor A, Menendez R, Cremades MJ, Pastor V, Llopis R, Aznar J. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir J 1997;10:603-9.
16. Hippo Y, Taniguchi H, Tsutsumi S, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233-40.
17. Tsutsumi S, Taketani T, Nishimura K, et al. Two distinct gene expression signatures in pediatric acute lymphoblastic leukemia with MLL rearrangements. Cancer Res 2003;63:4882-7.
18. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531-7.
19. Hippo Y, Watanabe K, Watanabe A, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64:2418-23.
20. Hippo Y, Yashiro M, Ishii M, et al. Differential gene expression profiles of scirrhous gastric cancer cells with high metastatic potential to peritoneum or lymph nodes. Cancer Res 2001;61:889-95.
21. Mukasa A, Ueki K, Matsumoto S, et al. Distinction in gene expression profiles of oligodendrogliomas with and without allelic loss of 1p. Oncogene 2002;21:3961-8.
22. Virtanen C, Ishikawa Y, Honjoh D, et al. Integrated classification of lung tumors and cell lines by expression profiling. Proc Natl Acad Sci U S A 2002;99:12357-62.
23. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
24. Ishii M, Hashimoto S, Tsutsumi S, et al. Direct comparison of GeneChip and SAGE on the quantitative accuracy in transcript profiling analysis. Genomics 2000;68:136-43.
25. Watanabe A, Hippo Y, Taniguchi H, et al. An opposing view on WWOX protein function as a tumor suppressor. Cancer Res 2003;63:8629-33.
26. Travis WD, Corrin B, Shimosato Y. Histological classification of lung and pleural tumors. In: Travis WD, Colby TV, Corrin B, Shimosato Y. Histological typing of lung and pleural tumors. 3rd ed. Heidelberg: Springer-Verlag; 1999. p. 21-66.
27. Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumors. 5th ed. New York: John Wiley; 1997.
28. Hsu NY, Ho HC, Chow KC, et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 2001;61:2727-31.
29. Yoshida N, Egami H, Yamashita J, et al. Immunohistochemical expression of SKALP/elafin in squamous cell carcinoma of human lung. Oncol Rep 2002;9:495-501.
30. Chen H, Lum A, Seifried A, Wilkens LR, Le Marchand L. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk. Cancer Res 1999;59:3045-8.
31. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000;28:1352-60.
32. De Heller-Milev M, Huber M, Panizzon R, Hohl D. Expression of small proline rich proteins in neoplastic and inflammatory skin diseases. Br J Dermatol 2000;143:733-40.
33. Yang M, Coles BF, Delongchamp R, Lang NP, Kadlubar FF. Effects of the ADH3, CYP2E1, and GSTP1 genetic polymorphisms on their expressions in Caucasian lung tissue. Lung Cancer 2002;38:15-21.
34. Cao D, Fan ST, Chung SS. Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem 1998;273:11429-35.
35. Hyndman DJ, Flynn TG. Sequence and expression levels in human tissues of a new member of the aldo-keto reductase family. Biochim Biophys Acta 1998;1399:198-202.
36. Scuric Z, Stain SC, Anderson WF, Hwang JJ. New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology 1998;27:943-50.
37. Auerbach O, Hammond EC, Garfinkel L. Bronchial epithelium and cigarette smoking. N Engl J Med 1979;300:1395-6.
38. Ol'khovskaia IG. Epithelial dysplasia of the bronchi and lung cancer. Arkh Patol 1985;47:20-5.
39. Wingo PA, Giovino GA, Miller DS, et al. Annual report to the nation on the status of lung cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst (Bethesda) 1999;91:675-90.
40. Crosas B, Hyndman DJ, Gallego O, et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003;373:973-9.
41. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996;10:940-54.
42. Harris CC, Sporn MB, Kaufman DG, Smith JM, Jackson FE, Saffiotti U. Histogenesis of squamous metaplasia in the hamster tracheal epithelium caused by vitamin A deficiency or benzo[a]pyrene-ferric oxide. J Natl Cancer Inst 1972;48:743-61.
43. Saffiotti U, Montesano R, Sellakumar AR, Borg SA. Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 1967;20:857-64.
44. Berg WJ, Divgi CR, Nanus DM, Motzer RJ. Novel investigative approaches for advanced renal cell carcinoma. Semin Oncol 2000;27:234-9.
45. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst 1999;91:1847-56.
46. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073-7.
47. Moore DM, Kalvakolanu DV, Lippman SM, et al. Retinoic acid and interferon in human cancer: mechanistic and clinical studies. Semin Hematol 1994;31:31-7.
48. Guruswamy S, Lightfoot S, Gold MA, et al. Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. J Natl Cancer Inst 2001;93:516-25.
49. Sun SY, Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 2002;41:41-55.
50. Albanes D, Heinonen OP, Taylor PR, et al. α-Tocopherol and β-carotene supplements and lung cancer incidence in the α-tocopherol, β-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:1560-70.
51. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of β carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5.